Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
136.97
+0.09 (+0.07%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
58
59
Next >
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
June 18, 2024
Eli Lilly stock has been on an astounding run. In 2009 its stock sold for 27.21 a share. It closed Tuesday at 891.46, up 3,149% from 2009.
Via
Investor's Business Daily
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
June 18, 2024
We ran a screener using Benzinga Pro to filter out three mega-cap stocks that are currently trading at attractive valuations.
Via
Benzinga
Obesity In Children - US Parents Face Tough Time To Access Recommended Treatment, Though Novo Nordisk's Drug Still Sees Strong Demand
June 18, 2024
U.S. parents face significant barriers to accessing intensive behavioral counseling for childhood obesity, with programs often unavailable, not covered by insurance, and requiring substantial time...
Via
Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
June 18, 2024
This stock may not be a slam dunk, but it's looking very promising.
Via
The Motley Fool
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
June 17, 2024
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.
Via
Investor's Business Daily
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
June 14, 2024
Via
Benzinga
Novo Nordisk Unusual Options Activity For June 13
June 13, 2024
Via
Benzinga
6 Analysts Have This To Say About Novo Nordisk
June 10, 2024
Via
Benzinga
Could Structure Therapeutics Become the Next Novo Nordisk?
June 17, 2024
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
Via
The Motley Fool
3 Best Stocks to Buy From the Fantastic 5
June 17, 2024
Although the best Fantastic 5 stocks offer much relevance and plenty of upside potential, they’re still underappreciated.
Via
InvestorPlace
Week Of June 16: What's In Store For The Markets
June 16, 2024
Lots of chairs are being removed as the music gets louder and faster. It is a great time to raise cash by harvesting some gains and selling losing positions.
Via
Talk Markets
Where Will Madrigal Pharmaceuticals Be in 3 Years?
June 15, 2024
The coast is clear for it to grow, for now.
Via
The Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
June 15, 2024
Want peace of mind about your investments? Consider these great stocks.
Via
The Motley Fool
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
June 14, 2024
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Via
Investor's Business Daily
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
Via
InvestorPlace
3 Stocks to Sell as Ozempic Surges in Popularity
June 14, 2024
GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity.
Via
InvestorPlace
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
June 14, 2024
They aren't the flashiest stocks, but they get the job done.
Via
The Motley Fool
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
June 14, 2024
Novo Nordisk's competition in the obesity drug market is heating up.
Via
The Motley Fool
Weight Loss Drugs: Are They Really Magic?
June 13, 2024
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs."
Via
The Motley Fool
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
June 13, 2024
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals.
Via
Benzinga
3 Stocks to Buy as Ozempic Surges in Popularity
June 13, 2024
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.
Via
InvestorPlace
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
June 12, 2024
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss...
Via
Benzinga
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be... Pets?
June 12, 2024
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pave the way.
Via
Benzinga
7 Trending Stocks With Momentum on Their Side
June 12, 2024
Trending stocks offer an opportunity to ride momentum higher and create quick returns for daring investors.
Via
InvestorPlace
Is Eli Lilly the Best Pharmaceutical Stock for You?
June 12, 2024
Eli Lilly is serving a market that may reach $100 billion.
Via
The Motley Fool
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
June 11, 2024
Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors.
Via
Benzinga
Exposures
Product Safety
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
June 11, 2024
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Via
The Motley Fool
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
June 10, 2024
Five mega companies may offer higher earnings and return potential with lower risk.
Via
Investor's Business Daily
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
June 10, 2024
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device.
Via
Investor's Business Daily
Exposures
Product Safety
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
June 10, 2024
Although they’re not necessarily the most exciting ideas, investors should turn to safe stocks to buy to manage the market’s ambiguity.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
58
59
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.